About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 122 record(s)
Req # A-2021-001850
Ministerial briefing notes prepared for Carolyn Bennett, minister of mental health and addictions, for a meeting sometime between January 19 2022 - February 1 2022 concerning the substance use emergency declaration called in the Yukon.Organization: Health Canada
June 2022
Req # A-2021-001949
All documents held by Health Canada regarding Risk Assessments reports, Test Reports, Inspection Reports, and Cosmetic Notification which include the terms : "tattoo", "tattoo ink" or "tattoo printer ink", combined with at least one of these terms: "organic solvents”, "solvents", "heavy metals", "pigments", "lithium", "cadmium", "lead". Date range is from year 1990 until January 1st, 2000.Organization: Health Canada
June 2022
Req # A-2021-002114
The screening acceptance letter(s) from Health Canada to any and all generic drug manufacturer(s) for any and all abbreviated new drug submissions (ANDS) for the following medicinal ingredients which appear on the list of Generic Drug Submissions under review dated March 15, 2022: atorvastatin, levetiracetam, ticagrelor.Organization: Health Canada
June 2022
Req # A-2022-000078
The Module 1.3.1 Note to reviewer indicating the brand name of the reference drug product and the dosage form of the generic drug in the list of generic drug submissions under review for the medicinal ingredient Gabapentin. The Screening Acceptance Letter from Health Canada to any and all generic drug manufacturers confirming completion of screening of any and all Abbreviated New Drug Submissions for gabapentin which appear on the list of Generic Drug Submissions Under Review (GSUR).Organization: Health Canada
June 2022
Req # A-2022-000087
All submissions to the consultation on "The Distinction Between Promotional and Non-promotional Messages and Activities for Health Products."Organization: Health Canada
June 2022
Req # A-2022-000088
The latest copies of the organisational charts for, Deputy Minister's Office of Health Canada, President's Office of the Public Health Agency of Canada (PHAC) and the Chief Public Health Officer's (CPHO's) Office. Timeline limited to the latest copies available, provided they are dated later than April 1, 2021.Organization: Health Canada
June 2022
Req # A-2022-000205
All documents regarding the removal of an Access to Information request from the Open Government portal (PHAC file A-2019-000094).Organization: Health Canada
June 2022
Req # A-2022-000208
All documents discussing the Prime Minister's statement where he called those who are unvaccinated misogynists and racists. Any communications regarding this statement and the handling of it.Organization: Health Canada
June 2022
Req # A-2022-000216
Sales data for the following active ingredients for the years 2015-2019: Atrazine, Linuron, Paraquat, Chlorothalonil Sector: Pest Management Regulatory Agency (PMRA).Organization: Health Canada
June 2022
Req # A-2022-000245
All records pertaining to describing the isolation of COVID 19, SARS-COV-2 VIRUS, that has directly come from a diseased human being, that has been isolated and purified, where the patient sample was not first combined with any other source of genetic material.Organization: Health Canada
June 2022